| Project/Area Number |
23K16303
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 58020:Hygiene and public health-related: including laboratory approach
|
|---|
| Research Institution | Hiroshima University |
|---|
Principal Investigator |
KO KO 広島大学, 医系科学研究科(医), 助教 (80910299)
|
|---|
| Project Period (FY) |
2023-04-01 – 2026-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2025: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2024: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2023: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | Hepatitis D Virus / Cambodia / ELISA / Screening / Hepatitis D Virus |
|---|
| Outline of Research at the Start |
We will examine anti-HDV through opportunistic test by means of commercially available ELISA kit, and in-house developed direct ELISA and Sandwich method to all HBsAg positive samples from pregnant women and their newborns in Siem Reap, Cambodia followed by molecular analysis.
|
| Outline of Annual Research Achievements |
I developed and validated an in-house direct ELISA method for detecting anti-HDV among 67 HBsAg positive pregnant women's stock serum collected in 2021 in Cambodia. Compared to a commercially available kit, the sensitivity was 50%, and the specificity was 95.4%. The overall anti-HDV prevalence among HBsAg positives was 5.97% (4/67). Subsequently, positive samples were tested for HDV RNA using nested RT-PCR with in-house developed universal primer sets, revealing that only 2 were HDV RNA positive (2.98%). Further amplification confirmed both belonged to HDV genotype 1. The study results were presented at APASL 2023 and the Japan Society of Hepatology conference in Otani. Currently, I am conducting a trial experiment on anti-HDV detection using dried blood spot (DBS) samples.
|
| Current Status of Research Progress |
Current Status of Research Progress
1: Research has progressed more than it was originally planned.
Reason
Over fifty percent of the project has been completed after repeated trial and experiments on development of in-house Direct ELISA method. Subsequently, the trial experiment on anti-HDV detection by in-house direct ELISA method using dried blood spot samples is on track and I expect to develop and validate before September 2024. The, I will subsequently continue for anti-HDV detection among all 67 positives pregnant women DBS and their children DBS. The result of the study have been presented as poster in both Japan Society of Hepatology conference in Otani and APASL Kyoto 2024.
|
| Strategy for Future Research Activity |
Subsequently after successful development and validation of In-house Direct ELISA based anti-HDV detection, I am now on track in developing in-house Direct ELISA based detection of anti-HDV using Dried Blood Spot samples, and planning to perform anti-HDV screening among children. The technique development is expected to complete by September 2024. Once the in-house method is validated, the anti-HDV screening will be performed in children using DBS samples.
|
